🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

7,888 results for “1” Clear

  1. TETRACOSACTIDE , BETAMETHASONE , Placebo of fludrocortisone, Placebo of hydrocortisone hemisuccinate, FLUDROCORTISONE , HYDROCORTISONE HEMISUCCINATE

    Pari Pharma GmbH

    Critically ill patients suffering from CIRCI

    phase 3 small molecule active

    1 trial

  2. TEV-50717

    Teva Pharma GmbH

    Tourette Syndrome

    phase 3 small molecule terminated

    3 trials

  3. TEV-50717

    Teva Pharma GmbH

    Cerebral Palsy, Dyskinetic

    phase 3 small molecule terminated

    2 trials

  4. TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment

    Almirall, S.A.

    Actinic Keratosis on the Face or Scalp

    phase 3 small molecule active

    1 trial

  5. TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Retatrutide, Retatrutide, TIRZEPATIDE, Placebo to match LY, Retatrutide, Placebo to match LY

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  6. TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  7. TLX-101-Tx + Lomustine

    Telix Innovations

    Neoplastic Disease

    phase 3 other active

    1 trial

  8. TMC125

    Elan Pharma International

    HIV-1

    phase 3 small molecule completed

    1 trial

  9. TNX-102 SL

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule terminated

    6 trials

  10. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    2 trials

  11. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  12. TNX-102 SL 2.8mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  13. TNX-102 SL 5.6 mg

    Tonix Pharmaceuticals Holding

    PTSD

    phase 3 small molecule completed

    1 trial

  14. TNX-102 SL Tablet 2.8 mg

    Tonix Pharmaceuticals Holding

    Primary Fibromyalgia

    phase 3 small molecule completed

    1 trial

  15. TNX-102 SL Tablet, 2.8 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule terminated

    1 trial

  16. TNX-102 SL Tablet, 2.8mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  17. TNX-102 SL Tablet, 5.6 mg

    Tonix Pharmaceuticals Holding

    Fibromyalgia

    phase 3 small molecule completed

    1 trial

  18. TNX-103

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension Associated With HFpEF

    phase 3 small molecule active

    2 trials

  19. TNX-103

    TENAX THERAPEUTICS, INC.

    Pulmonary Hypertension

    phase 3 small molecule active

    1 trial

  20. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial

  21. TOCILIZUMAB, Tarlatamab, DEXAMETHASONE, Placebo for Tarlatamab (AMG-757), PARACETAMOL , ELECTROLYTES , PREDNISOLONE , Tarlatamab, VASOPRESSIN (ARGIPRESSIN) , SILTUXIMAB

    Amgen

    Limited-Stage Small-Cell Lung Cancer (LS SCLC)

    phase 3 small molecule active

    1 trial

  22. TOFACITINIB, TOFACITINIB, Tofacitinib citrate

    Pfizer Australia Pty Ltd

    Juvenile Idiopathic Arthritis (JIA)

    phase 3 small molecule active

    1 trial

  23. TOOKAD 183 mg powder for solution for injection, PADELIPORFIN

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  24. TOPOTECAN, TOPOTECAN, IRINOTECAN, TOPOTECAN, lurbinectedin, TOPOTECAN

    Lacuna Pharma Pty Ltd

    Small Cell Lung Cancer (SCLC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources